Potential link to brain inflammation may explain the connection between MS and fatigue

Up to 60 percent of patients with multiple sclerosis (MS) report that fatigue is the disease's most debilitating symptom. And yet, fatigue remains one of MS's mysteries -- despite its prevalence and significance, the root cause of the symptom remains unclear.

In a study published in Neurology Neuroimmunology & Neuroinflammation, investigators from Brigham and Women's Hospital used positron emission technology (PET) imaging to look for brain's immune cells that may become erroneously activated in MS, leading to fatigue.

The team describes a potential link to brain inflammation that may help explain the connection between MS and fatigue.

Fatigue correlates poorly with the conventional markers of multiple sclerosis -- the brain lesions we see using magnetic resonance imaging (MRI) don't associate well with fatigue. So we went searching for a hidden pathology; something that has gone undetected until now in the context of fatigue in MS."

Tarun Singhal, MD, Study Corresponding Author, Neurologist and Nuclear Medicine Physician, Department of Neurology, Brigham and Women's Hospital

Singhal is also the director of the PET Imaging Program in Neurologic Diseases at the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital.

Singhal and colleagues used a second-generation radioligand known as [F-18]PBR06 to conduct PET imaging. Singhal describes this tracer as a "radiolabel detective" that can snoop for clues.

Once injected, the tracer travels to the brain, binds to abnormally activated immune cells called microglia (and to some extent, additionally, to other immune and support cells called astrocytes) and emits gamma rays that can be picked up by a scanner.

The team performed PET scans on 12 MS patients and 10 healthy controls, finding strong correlations between MS patients' self-reported fatigue risk scores and activation of immune cells in very specific regions of the brain.

These regions included the substantia nigra -- which translates literally to "the dark substance." The substantia nigra is the site where dopamine is produced (dopaminergic neurons appear darker on pathology, giving the region its name).

Dopamine plays many roles in the body and is required for stimulating attention and wakefulness patterns in the brain. Several additional areas of the brain also correlated significantly with fatigue scores, but there was no association between fatigue scores and brain atrophy and lesion load in MS patients.

The researchers note that given the study's small sample size, additional study is needed to validate their findings.

"We detected a widespread network of very specific regions whose inflammation correlates with fatigue scores and all have implications for contributions to fatigue," said Singhal.

"We are now pursuing further study to confirm our findings in a larger sample size and are looking at interactions between neurochemistry and neuroinflammation."

Source:
Journal reference:

Singhal, T., et al. (2020) Regional Microglial Activation in Substantia Nigra is linked with Fatigue in Multiple Sclerosis. Neurology: Neuroimmunology & Neuroinflammation. doi.org/10.1212/NXI.0000000000000854.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
$1 million grant supports research on groundbreaking therapies for MS